Our core medical business (AtCor Medical) develops, markets, and distributes medical technologies that measure patient risk for hypertension, cardiovascular disease (CVD), and other related vascular disorders. Our wearable and "smart device" division (CardieX Labs in partnership with Blumio), develops non-invasive wearable technologies that identify patient risk profiles for hypertension, CVD, and related disorders. Our telehealth group (via our investment in inHealth) develops and provides clinically based health coaching to health insurance networks, private practice, and medical device companies.
Our health solutions and IP have the potential to disrupt multiple multi-billion dollar markets in preventative diagnostics, patient management, smart wearables, and consumer/digital health. The current focus is cardiovascular diseases (CVD) and heart health – the #1 cause of premature death globally. Our long-term future lies in developing large-scale health technologies in other significant global wellness markets, such as diabetes management, weight loss management, orthopedic health, and urological health.
Founded in Sydney in 1994 by Dr. Michael O’Rourke as AtCor Medical, our company launched with a focus on hypertension management and developed our proprietary and market-leading SphygmoCor® technology. AtCor changed its name to CardieX in 2018 to better reflect its focus on developing a wide range of global health solutions and technologies.